Fusidic acid oral - Cempra Pharmaceuticals

Drug Profile

Fusidic acid oral - Cempra Pharmaceuticals

Alternative Names: CEM-102; SQ-16603; Taksta

Latest Information Update: 01 Mar 2017

Price : $50

At a glance

  • Originator Unknown
  • Developer Cempra Pharmaceuticals
  • Class Antibacterials; Cholestadienes; Sterols
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone and joint infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase II/III Bone and joint infections
  • No development reported Cystic fibrosis-associated respiratory tract infections; Osteomyelitis

Most Recent Events

  • 24 Feb 2017 Positive top-line safety and efficacy data from a phase III trial in Skin and soft tissue infections released by Cempras
  • 01 Nov 2016 Cempra completes a phase III trial in Skin and soft tissue infections (In adolescents, In adults) in USA (PO) (NCT02570490)
  • 01 Dec 2015 Phase-II/III clinical trials in Bone and joint infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top